AAPL   381.61 (-0.29%)
GOOGL   1,516.16 (-0.16%)
AMZN   3,175.95 (-0.21%)
NVDA   419.36 (-0.24%)
BABA   259.38 (-0.84%)
MU   50.14 (+0.32%)
GE   6.69 (+1.67%)
AMD   56.25 (-1.76%)
T   29.78 (+0.81%)
ACB   11.88 (+0.93%)
F   5.98 (+2.22%)
DIS   118.34 (+1.30%)
BA   175.73 (+1.41%)
AAPL   381.61 (-0.29%)
GOOGL   1,516.16 (-0.16%)
AMZN   3,175.95 (-0.21%)
NVDA   419.36 (-0.24%)
BABA   259.38 (-0.84%)
MU   50.14 (+0.32%)
GE   6.69 (+1.67%)
AMD   56.25 (-1.76%)
T   29.78 (+0.81%)
ACB   11.88 (+0.93%)
F   5.98 (+2.22%)
DIS   118.34 (+1.30%)
BA   175.73 (+1.41%)
AAPL   381.61 (-0.29%)
GOOGL   1,516.16 (-0.16%)
AMZN   3,175.95 (-0.21%)
NVDA   419.36 (-0.24%)
BABA   259.38 (-0.84%)
MU   50.14 (+0.32%)
GE   6.69 (+1.67%)
AMD   56.25 (-1.76%)
T   29.78 (+0.81%)
ACB   11.88 (+0.93%)
F   5.98 (+2.22%)
DIS   118.34 (+1.30%)
BA   175.73 (+1.41%)
AAPL   381.61 (-0.29%)
GOOGL   1,516.16 (-0.16%)
AMZN   3,175.95 (-0.21%)
NVDA   419.36 (-0.24%)
BABA   259.38 (-0.84%)
MU   50.14 (+0.32%)
GE   6.69 (+1.67%)
AMD   56.25 (-1.76%)
T   29.78 (+0.81%)
ACB   11.88 (+0.93%)
F   5.98 (+2.22%)
DIS   118.34 (+1.30%)
BA   175.73 (+1.41%)
Log in

NASDAQ:IMACIMAC Stock Price, Forecast & News

$1.22
+0.04 (+3.39 %)
(As of 07/10/2020 10:48 AM ET)
Add
Compare
Today's Range
$1.17
Now: $1.22
$1.22
50-Day Range
$1.22
MA: $1.54
$2.17
52-Week Range
$0.42
Now: $1.22
$5.35
Volume800 shs
Average Volume285,707 shs
Market Capitalization$12.21 million
P/E RatioN/A
Dividend YieldN/A
Beta-3.66
IMAC Holdings, Inc. operates a chain of integrated medicine and chiropractic regeneration centers. The company's outpatient clinics provide regenerative, orthopedic, and minimally invasive procedures and therapies to patients with back pain, knee pain, joint pain, ligament and tendon damage, and other related soft tissue conditions. As of September 17, 2018, it had 11 clinics, including 6 owned and 5 managed clinics in Kentucky, Missouri, and Tennessee, the United States. The company was founded in 2000 and is based in Brentwood, Tennessee.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.09 out of 5 stars


Industry, Sector and Symbol

Industry Specialty outpatient clinics, not elsewhere classified
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IMAC
CUSIPN/A
CIKN/A
Phone844-266-4622

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$15.13 million
Book Value$0.93 per share

Profitability

Net Income$-6,500,000.00

Miscellaneous

EmployeesN/A
Market Cap$12.21 million
Next Earnings Date8/21/2020 (Estimated)
OptionableNot Optionable

Receive IMAC News and Ratings via Email

Sign-up to receive the latest news and ratings for IMAC and its competitors with MarketBeat's FREE daily newsletter.

IMAC (NASDAQ:IMAC) Frequently Asked Questions

How has IMAC's stock been impacted by COVID-19 (Coronavirus)?

IMAC's stock was trading at $0.82 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, IMAC stock has increased by 48.8% and is now trading at $1.22. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of IMAC?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IMAC in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for IMAC.

When is IMAC's next earnings date?

IMAC is scheduled to release its next quarterly earnings announcement on Friday, August 21st 2020. View our earnings forecast for IMAC.

How were IMAC's earnings last quarter?

IMAC Holdings Inc (NASDAQ:IMAC) issued its earnings results on Thursday, May, 14th. The company reported ($0.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.01. The business earned $3.32 million during the quarter, compared to the consensus estimate of $5.72 million. IMAC had a negative return on equity of 80.08% and a negative net margin of 41.20%. View IMAC's earnings history.

What price target have analysts set for IMAC?

2 Wall Street analysts have issued 1-year target prices for IMAC's stock. Their forecasts range from $4.50 to $4.50. On average, they expect IMAC's stock price to reach $4.50 in the next year. This suggests a possible upside of 268.9% from the stock's current price. View analysts' price targets for IMAC.

Has IMAC been receiving favorable news coverage?

News articles about IMAC stock have been trending positive recently, according to InfoTrie Sentiment. The research group rates the sentiment of media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. IMAC earned a coverage optimism score of 3.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View the latest news about IMAC.

Are investors shorting IMAC?

IMAC saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 99,400 shares, an increase of 18.1% from the June 15th total of 84,200 shares. Based on an average trading volume of 1,030,000 shares, the short-interest ratio is presently 0.1 days. Approximately 1.6% of the company's shares are short sold. View IMAC's Current Options Chain.

Who are some of IMAC's key competitors?

What other stocks do shareholders of IMAC own?

Who are IMAC's key executives?

IMAC's management team includes the following people:
  • Mr. Jeffrey S. Ervin M.B.A., CEO & Director (Age 41)
  • Mr. D. Anthony Bond CPA, Chief Financial Officer (Age 57)
  • Dr. Matthew C. Wallis, COO & Director (Age 45)
  • Mr. Jeff Ervin, Chief Exec. Officer
  • Dr. Ian A. White Ph.D., Chief Scientific Officer (Age 44)

When did IMAC IPO?

(IMAC) raised $4 million in an IPO on the week of February 11th 2019. The company issued 900,000 shares at a price of $5.00 per share. Dawson James Securities and Cuttone served as the underwriters for the IPO.

What is IMAC's stock symbol?

IMAC trades on the NASDAQ under the ticker symbol "IMAC."

How do I buy shares of IMAC?

Shares of IMAC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is IMAC's stock price today?

One share of IMAC stock can currently be purchased for approximately $1.22.

How big of a company is IMAC?

IMAC has a market capitalization of $12.21 million and generates $15.13 million in revenue each year. The company earns $-6,500,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

What is IMAC's official website?

The official website for IMAC is www.imacregeneration.com.

How can I contact IMAC?

IMAC's mailing address is 1605 WESTGATE CIRCLE, BRENTWOOD TN, 37027. The company can be reached via phone at 844-266-4622 or via email at [email protected]

This page was last updated on 7/10/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.